Zacks: Analysts Anticipate Syneos Health, Inc. (NASDAQ:SYNH) Will Post Earnings of $1.20 Per Share

Equities analysts expect Syneos Health, Inc. (NASDAQ:SYNHGet Rating) to report $1.20 earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syneos Health’s earnings, with the highest EPS estimate coming in at $1.22 and the lowest estimate coming in at $1.19. Syneos Health posted earnings per share of $0.97 during the same quarter last year, which would indicate a positive year-over-year growth rate of 23.7%. The business is expected to announce its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Syneos Health will report full year earnings of $5.14 per share for the current fiscal year, with EPS estimates ranging from $4.99 to $5.20. For the next financial year, analysts forecast that the business will post earnings of $5.74 per share, with EPS estimates ranging from $5.50 to $5.95. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Syneos Health.

Syneos Health (NASDAQ:SYNHGet Rating) last released its earnings results on Friday, April 29th. The company reported $1.01 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.06. Syneos Health had a return on equity of 13.33% and a net margin of 4.54%. The business had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.32 billion. During the same quarter last year, the firm posted $0.66 earnings per share. The business’s revenue was up 10.5% compared to the same quarter last year.

SYNH has been the topic of several research reports. Barclays cut their price target on Syneos Health from $115.00 to $105.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Jefferies Financial Group lowered Syneos Health from a “buy” rating to a “hold” rating and cut their price target for the company from $101.00 to $75.00 in a research note on Monday, April 25th. Mizuho restated a “buy” rating and set a $94.00 price target on shares of Syneos Health in a research note on Friday, May 20th. StockNews.com initiated coverage on Syneos Health in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Finally, TheStreet lowered Syneos Health from a “b” rating to a “c+” rating in a research note on Wednesday, May 18th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Syneos Health has an average rating of “Buy” and an average price target of $98.40.

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in Syneos Health by 16.3% in the first quarter. BlackRock Inc. now owns 11,527,780 shares of the company’s stock worth $933,174,000 after acquiring an additional 1,617,330 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Syneos Health by 0.3% in the first quarter. Vanguard Group Inc. now owns 9,724,346 shares of the company’s stock worth $787,185,000 after acquiring an additional 30,725 shares in the last quarter. Clearbridge Investments LLC boosted its holdings in Syneos Health by 3.3% in the first quarter. Clearbridge Investments LLC now owns 3,902,162 shares of the company’s stock worth $315,880,000 after acquiring an additional 125,011 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Syneos Health by 33.7% in the first quarter. Massachusetts Financial Services Co. MA now owns 2,868,800 shares of the company’s stock worth $232,229,000 after acquiring an additional 723,812 shares in the last quarter. Finally, State Street Corp boosted its holdings in Syneos Health by 2.4% in the first quarter. State Street Corp now owns 2,660,420 shares of the company’s stock worth $215,361,000 after acquiring an additional 61,351 shares in the last quarter. Institutional investors own 98.38% of the company’s stock.

SYNH stock traded up $0.16 during midday trading on Wednesday, reaching $70.72. The company’s stock had a trading volume of 366,203 shares, compared to its average volume of 703,880. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.09 and a current ratio of 1.09. The stock has a fifty day simple moving average of $76.29 and a two-hundred day simple moving average of $86.31. Syneos Health has a 1 year low of $66.73 and a 1 year high of $104.18. The firm has a market capitalization of $7.25 billion, a price-to-earnings ratio of 30.61 and a beta of 1.79.

Syneos Health Company Profile (Get Rating)

Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Read More

Get a free copy of the Zacks research report on Syneos Health (SYNH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.